Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma

August 20, 2015 11:29 AM EDT

BMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More